氩氦刀冷冻消融联合肝动脉插管化疗栓塞治疗原发性肝癌的疗效研究

Efficacy of Argon-Helium Cryoablation Combined with Transcatheter Arterial Chemoembolization in the Treatment of Primary Hepatic Cancer

目的探讨氩氦刀冷冻消融联合肝动脉化疗栓塞（TACE）治疗原发性肝癌的临床疗效。方法回顾性分析行介入治疗的32例原发性肝癌患者的临床资料,其中16例单纯应用TACE治疗（对照组）,16例采用TACE联合氩氦刀冷冻消融治疗（实验组）,随访6月~2年。比较2组患者的6月、1年、2年的生存率,治疗有效率,肿瘤坏死程度及AFP变化。结果实验组与对照组半年、1年、2年的生存率分别为100.0%、75.0%、50.0%及93.7%、50.0%、31.2%,治疗组与对照组治疗总有效率分别为75.0%、43.7%,肿瘤完全坏死率分别为62.5%、18.8%,AFP转阴率分别为62.5%、31.3%。2组间在1年、2年的生存率,治疗总有效率,肿瘤完全坏死率及AFP转阴率方面的差异均有统计学意义（P均〈0.05）。结论氩氦刀冷冻消融联合TACE治疗原发性肝癌是一种有效的治疗方法。

Objective To investigate the efficacy of Argon-Helium cryoablation combined with transcatheter arterial chemoembolization（TACE） for primary hepatic cancer.Methods A retrospective analysis of clinical data of 32 patients with primary hepatic cancer was conducted.The study group（n = 16） were treated by Argon-Helium cryoablation combined with TACE,the control group（n = 16） were treated by TACE.All the patients were followed-up for 6 months to 2 years.6-month,1-,2-year survival rates,total effective rates,complete necrosis rates and AFP negative rates of the 2 groups were compared.Results 6-month,1-,2-year survival rates in the study group and the control group were 100.0%,75.0%,50.0% and 93.7%,50.0%,31.2%,respectively,the total effective rates in the study group and the control group were 75.0%,43.7%,the complete necrosis rates in the study group and the control group were 62.5%,18.8%,AFP negative rate was 62.5%,31.3%,There had significant difference in 1-,2-year survival rates,total effective rate,complete necrosis rate and AFP negative rate between the 2 groups（P〈0.05）.Conclusion Argon-Helium cryoablation combined with TACE is an effective and safe treatment for primary hepatic cancer.